Dittrich Ralf, Hackl Janina, Lotz Laura, Hoffmann Inge, Beckmann Matthias W
Department of Gynecology and Obstetrics, Erlangen University Hospital, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Department of Gynecology and Obstetrics, Erlangen University Hospital, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Fertil Steril. 2015 Feb;103(2):462-8. doi: 10.1016/j.fertnstert.2014.10.045. Epub 2014 Dec 6.
To report the results of 20 orthotopic retransplantations of cryopreserved ovarian tissue after cancer treatment.
Retrospective analysis.
Tertiary gynecology department.
PATIENT(S): Twenty patients with malignant disease: 11 with hematological malignancies (55%), four with breast cancer (20%), three with anal cancer (15%), and two with ovarian cancer (10%); the mean age before oncological treatment was 30.5 years.
INTERVENTION(S): Ovarian tissue was removed from patients in various centers in Germany in 2005-2009. All patients received chemotherapy and/or radiotherapy. Afterward, 17 patients had complete premature ovarian insufficiency, while three still showed some ovarian activity. Overnight transportation of tissue before freezing was necessary in eight cases. Cryopreservation followed slow freezing protocols in all cases. Retransplantation was performed at Erlangen University Hospital 3.75 years after extraction, on average. Thawed tissue was transplanted into a peritoneal pouch in the broad ligament region, below the tube, in 16 cases. Fragments were sutured both onto the remaining ovary and into a peritoneal pouch in four cases.
MAIN OUTCOME MEASURE(S): Restoration of ovarian activity, pregnancy, birth.
RESULT(S): Ovarian activity resumed in all patients except one. Seven patients conceived, with one miscarriage and four ongoing pregnancies. Four patients delivered healthy babies. One pregnancy and live birth after oocyte donation need to be considered separately.
CONCLUSION(S): These data clearly demonstrate that preserving fertility by cryopreserving ovarian tissue is a successful and safe clinical option that can be considered for selected cancer patients.
报告20例癌症治疗后冻存卵巢组织原位再移植的结果。
回顾性分析。
三级妇科科室。
20例恶性疾病患者:11例血液系统恶性肿瘤(55%),4例乳腺癌(20%),3例肛门癌(15%),2例卵巢癌(10%);肿瘤治疗前的平均年龄为30.5岁。
2005年至2009年期间,从德国各中心的患者体内取出卵巢组织。所有患者均接受了化疗和/或放疗。之后,17例患者出现完全性卵巢早衰,3例仍有一定卵巢活性。8例患者在冷冻前需要对组织进行过夜运输。所有病例均采用慢速冷冻方案进行冷冻保存。平均在取出组织3.75年后,于埃尔朗根大学医院进行再移植。16例患者将解冻后的组织移植到阔韧带区域输卵管下方的腹膜袋中。4例患者将组织碎片分别缝合到剩余卵巢和腹膜袋中。
卵巢活性恢复、妊娠、分娩。
除1例患者外,所有患者的卵巢活性均得以恢复。7例患者怀孕,其中1例流产,4例妊娠仍在继续。4例患者分娩出健康婴儿。1例卵母细胞捐赠后的妊娠和活产需单独考虑。
这些数据清楚地表明,通过冻存卵巢组织来保留生育能力是一种成功且安全的临床选择,可用于部分选定的癌症患者。